| Relation: |
https://www.med-sovet.pro/jour/article/view/8510/7481; Хаар Х, Хайзе Т. Сверхбыстродействующий инсулин аспарт: фармакокинетические и фармакодинамические свойства и их влияние на клинические эффекты. Сахарный диабет. 2020;23(2):140-160. https://doi.org/10.14341/DM12357.; Демидова ТЮ, Измайлова МЯ. Сверхбыстродействующий инсулин аспарт - от портрета инсулина к портретам пациентов. Медицинский совет. 2021;(7):8-16. https://doi.org/10.21518/2079-701X-2021-7-8-16.; Heise T, Stender-Petersen K, Hovelmann U, Jacobsen JB, Nosek L, Zijlstra E, Haahr H. Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus. Clin Pharmacokinet. 2017;56(6):649-660. https://doi.org/10.1007/s40262-016-0473-5.; Саверская ЕН, Кокшарова ЕО, Носков СМ, Заикин ПГ, Банко ВВ, Арефьева АН. Результаты оценки биоподобия препаратов инсулина аспарт отечественного и зарубежного производства с использованием метода гиперинсулинемического эугликемического клэмпа и исследования применения нового сверхбыстродействующего отечественного биосимиляра в помпах. Медицинский совет. 2024;18(1):43-50. https://doi.org/10.21518/ms2024-023.; Булгакова СВ, Саверская ЕН, Шаронова ЛА, Долгих ЮА, Косарева ОВ. Биосимиляр аналога инсулина гларгин: доказанная безопасность, эффективность, взаимозаменяемость. Медицинский совет. 2022;16(23):207-214. https://doi.org/10.21518/2079-701X-2022-16-23-207-214.; Evans M, Wilkinson M, Giannpolou A. Fast-Acting Insulin Aspart: The Rationale for a New Mealtime Insulin. Diabetes Ther. 2019;1O(5):1793-180O. https://doi.org/10.1007/s13300-019-00685-0.; Evans M, Ceriello A, Danne T, De Block C, DeVries JH, Lind M et al. Use of fast-acting insulin aspart in insulin pump therapy in clinical practice. Diabetes Obes Metab. 2019;21(9):2039-2047. https://doi.org/10.1111/dom.13798.; McNeal CJ, Meininger CJ, Reddy D, Wilborn CD, Wu G. Safety and effectiveness of arginine in adults. J Nutr. 2016;146(12):2587S-2593S. https://doi.org/10.3945/jn.116.234740.; Kildegaard J, Buckley ST, Nielsen RH, Povlsen GK, Seested T, Ribel U et al. Elucidating the mechanism of absorption of fast-acting insulin aspart: the role of niacinamide. Pharm Res. 2019;36(3):49. https://doi.org/10.1007/s11095-019-2578-7.; Billion L, Charleer S, Registrar VLJ, Registrar SMJ, Registrar VKJ, De Block N et al. Glucose control using fast-acting insulin aspart in a real-world setting: A 1-year, two-centre study in people with type 1 diabetes using continuous glucose monitoring. Diabetes Obes Metab. 2021;23(12):2716-2727. https://doi.org/10.1111/dom.14527.; Dutta D, Mohindra R, Mahajan K, Sharma M. Performance of Fast-Acting Aspart Insulin as Compared to Aspart Insulin in Insulin Pump for Managing Type 1 Diabetes Mellitus: A Meta-Analysis. Diabetes Metab J. 2023;47(1):72-81. https://doi.org/10.4093/dmj.2022.0035.; Buse JB, Carlson AL, Komatsu M, Mosenzon O, Rose L, Liang B et al. Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: Efficacy and safety from a randomized double-blind trial. Diabetes Obes Metab. 2018;20(12):2885-2893. https://doi.org/10.1111/dom.13545.; Lind M, Catrina SB, Ekberg NR, Gerward S, Halasa T, Hellman J et al. Fast-Acting Insulin Aspart in Patients with Type 1 Diabetes in Real-World Clinical Practice: A Noninterventional, Retrospective Chart and Database Study. Diabetes Ther. 2023;14(9):1563-1575. https://doi.org/10.1007/s13300-023-01444-y.; Каронова ТЛ, Майоров АЮ. Изучение эквивалентности и сопоставимой иммуногенности биосимиляра инсулина аспарт в сравнении с зарегистрированным аналогом. Медицинский совет. 2022;16(10):75-82. https://doi.org/10.21518/2079-701X-2022-16-10-75-82.; Дедов ИИ, Шестакова МВ, Петеркова ВА, Майоров АЮ, Галстян ГР, Викулова ОК. Проект рекомендаций Российской ассоциации эндокринологов по применению биосимиляров инсулина. Сахарный диабет. 2021;24(1):76-79. Режим доступа: https://www.dia-endojournals.ru/jour/article/view/12739.; Shiramoto M, Nishida T, Hansen AK, Haahr H. Fast-acting insulin aspart in Japanese patients with type 1 diabetes: Faster onset, higher early exposure and greater early glucose-lowering effect relative to insulin aspart. J Diabetes Investig. 2018;9(2):303-310. https://doi.org/10.1111/jdi.12697.; Haahr H, Pieber TR, Mathieu C, Gondolf T, Shiramoto M, Erichsen L, Heise T. Clinical Pharmacology of Fast-Acting Insulin Aspart Versus Insulin Aspart Measured as Free or Total Insulin Aspart and the Relation to Anti-Insulin Aspart Antibody Levels in Subjects with Type 1 Diabetes Mellitus. Clin Pharmacokinet. 2019;58(5):639-649. https://doi.org/10.1007/s40262-018-0718-6.; Pieber TR, Svehlikova E, Brunner M, Halberg IB, Due Thomsen KM, Haahr H. Fast-acting insulin aspart in people with type 2 diabetes: Earlier onset and greater initial exposure and glucose-lowering effect compared with insulin aspart. Diabetes Obes Metab. 2019;21(9):2068-2075. https://doi.org/10.1111/dom.13767.; Hovelmann U, Heise T, Nosek L, Sassenfeld B, Thomsen KMD, Haahr H. Pharmacokinetic Properties of Fast-Acting Insulin Aspart Administered in Different Subcutaneous Injection Regions. Clin Drug Investig. 2017;37(5):503-509. https://doi.org/10.1007/s40261-017-0499-y.; Koufakis T, Dhatariya KK, Kotsa K. Potential Role of Ultrafast-acting Insulin Analogues in the Treatment of Diabetic Ketoacidosis. J Clin Endocrinol Metab. 2022;107(10):e4259-e4260. https://doi.org/10.1210/clinem/dgac301.; Mathieu C, Bode BW, Franek E, Philis-Tsimikas A, Rose L, Graungaard T et al. Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treatto-target, phase III trial. Diabetes Obes Metab. 2018;20(5):1148-1155. https://doi.org/10.1111/dom.13205.; Russell-Jones D, Bode BW, de Block C, Franek E, Heller SR, Mathieu C et al. Fast-acting insulin aspart improves glycemic control in basal-bolus treatment for type 1 diabetes: Results of a 26-week multicenter, active-controlled, treat-to-target, randomized, parallelgroup trial (onset 1). Diabetes Care. 2017;40(7):943-950. https://doi.org/10.2337/dc16-1771.; Danne T, Schweitzer MA, Keuthage W, Kipper S, Kretzschmar Y, Simon J et al. Impact of Fast-Acting Insulin Aspart on Glycemic Control in Patients with Type 1 Diabetes Using Intermittent-Scanning Continuous Glucose Monitoring Within a Real-WorldSetting: The GoBolus Study. Diabetes Technol Ther. 2021;23(3):203-212. https://doi.org/10.1089/dia.2020.0360.; Bowering K, Case C, Harvey J, Reeves M, Sampson M, Strzinek R et al. Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial. Diabetes Care. 2017;40(7):951-957. https://doi.org/10.2337/dc16-1770.; Lane WS, Favaro E, Rathor N, Jang HC, Kjærsgaard MIS, Oviedo A et al. A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (ONSET 9). Diabetes Care. 2020;43(8):1710-1716. https://doi.org/10.2337/dc19-2232.; Rodbard HW, Tripathy D, Vidrio Velazquez M, Demissie M, Tamer SC, Piletic M. Adding fast-acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: A randomized, 18-week, open-label, phase 3 trial (onset 3). Diabetes Obes Metab. 2017;19(10):1389-1396. https://doi.org/10.1111/dom.12955.; Svehlikova E, Mursic I, Augustin T, Magnes C, Gerring D, Jezek J et al. Pharmacokinetics and Pharmacodynamics of Three Different Formulations of Insulin Aspart: A Randomized, Double-Blind, Crossover Study in Men With Type 1 Diabetes. Diabetes Care. 2021;44(2):448-455. https://doi.org/10.2337/dc20-1017.; Cengiz E, Bode B, Van Name M, Tamborlane WV. Moving toward the ideal insulin for insulin pumps. Expert Rev Med Devices. 2016;13(1):57-69. https://doi.org/10.1586/17434440.2016.1109442.; Fatourechi MM, Kudva YC, Murad MH, Elamin MB, Tabini CC, Montori VM. Clinical review: Hypoglycemia with intensive insulin therapy: a systematic review and meta-analyses of randomized trials of continuous subcutaneous insulin infusion versus multiple daily injections. J Clin Endocrinol Metab. 2009;94(3):729-740. https://doi.org/10.1210/jc.2008-1415.; Wei J, Wang Y. Effectiveness of Faster Aspart versus Insulin Aspart in Children with Type 1 Diabetes: A Meta-Analysis. Iran J Public Health. 2024;53(1):23-34. https://doi.org/10.18502/ijph.v53i1.14680.; Klonoff DC, Evans ML, Lane W, Kempe HP, Renard E, DeVries JH et al. A ran-domized, multicentre trial evaluating the efficacy and safety of fast-acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5). Diabetes Obes Metab. 2019;21(4):961-967. https://doi.org/10.1111/dom.13610.; Basu A, Pieber TR, Hansen AK, Sach-Friedl S, Erichsen L, Basu R, Haahr H. Greater early postprandial suppression of endogenous glucose production and higher initial glucose disappearance is achieved with fast-acting insulin aspart compared with insulin aspart. Diabetes Obes Metab. 2018;20(7):1615-1622. https://doi.org/10.1111/dom.13270.; Ozer K, Cooper AM, Ahn LP, Waggonner CR, Blevins TC. Fast Acting Insulin Aspart Compared with Insulin Aspart in the Medtronic 670G Hybrid Closed Loop System in Type 1 Diabetes: An Open Label Crossover Study. Diabetes Technol Ther. 2021;23(4):286-292. https://doi.org/10.1089/dia.2020.0500.; Zijlstra E, Demissie M, Graungaard T, Heise T, Nosek L, Bode B. Investigation of Pump Compatibility of Fast-Acting Insulin Aspart in Subjects With Type 1 Diabetes. J Diabetes Sci Technol. 2018;12(1):145-151. https://doi.org/10.1177/1932296817730375.; Beck RW, Russell SJ, Damiano ER, El-Khatib FH, Ruedy KJ, Balliro C, Li Z, Calhoun P. A Multicenter Randomized Trial Evaluating Fast-Acting Insulin Aspart in the Bionic Pancreas in Adults with Type 1 Diabetes. Diabetes Technol Ther. 2022;24(10):681-696. https://doi.org/10.1089/dia.2022.0167.; Yadav A, Kumar R, Dayal D, Yadav J, Pattanaik S, Patil A. Effect of Postmeal Fast-Acting Insulin Aspart Injection on the Frequency of Hypoglycemia among Pre-School Children with Type 1 Diabetes: An Open-Label, Cross-Over, Randomized Control Trial. Indian J Pediatr. 2023. https://doi.org/10.1007/s12098-023-04844-x.; Senior P, Hramiak I. Fast-Acting Insulin Aspart and the Need for New Mealtime Insulin Analogues in Adults With Type 1 and Type 2 Diabetes: A Canadian Perspective. Can J Diabetes. 2019;43(7):515-523. https://doi.org/10.1016/j.jcjd.2019.01.004.; Paquot N, Scheen AJ. Faster aspart insulin (FIASP®). Rev Med Liege. 2018;73(4):211-215. Available at: https://pubmed.ncbi.nlm.nih.gov/29676875/.; Fath M, Danne T, Biester T, Erichsen L, Kordonouri O, Haahr H. Faster-acting insulin aspart provides faster onset and greater early exposure vs insulin aspart in children and adolescents with type 1 diabetes mellitus. Pediatr Diabetes. 2017;18(8):903-910. https://doi.org/10.1111/pedi.12506.; Wong EY, Kroon L. Ultra-Rapid-Acting Insulins: How Fast Is Really Needed? Clin Diabetes. 2021;39(4):415-423. https://doi.org/10.2337/cd20-0119. |